ASND$248.830.97%-2.44
After Hours: 248.98+0.15 +0.06%
Ascendis Pharma A S (ASND)
Date: 2026-11-02 16:00O: 252.55H: 254.62L: 248.68C: 248.83Vol: 408.9k
Ascendis Pharma A S stock is traded at $248.83, with a volume of 408,944. It is down -0.97% in the last 24 hours and up +9.20% over the past month. Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
Previous Close:
$251.27
Open:
$252.55
24h Volume:
408,944
Relative Volume:
0.77
Market Cap:
$16.37B
Revenue:
$1.01B
Net Income/Loss:
$581.90M
P/E Ratio:
28.04
EPS:
$8.87
Net Cash Flow:
$50.57M
1W Performance:
+1.50%
1M Performance:
+9.20%
6M Performance:
+12.63%
1Y Performance:
+23.43%
1-Day Range:
$248.68$254.62
1-Week Range:
$243.45$255.61
52-Week Range:
$188.07$282.15
Ascendis Pharma A S Stock (ASND) Company Profile
Compare ASND vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|
ASND Ascendis Pharma A S | $16.37B | $1.01B | $581.90M | $50.57M | $8.87 |
 VRTX Vertex Pharmaceuticals Inc | $140.94B | $12.59B | $4.41B | $3.80B | $16.87 |
 REGN Regeneron Pharmaceuticals Inc | $99.46B | $16.90B | $4.82B | $3.83B | $41.04 |
 MRNA Moderna Inc | $88.17B | $2.23B | -$3.15B | -$1.24B | -$8.15 |
 ARGX Argen X Se Adr | $55.03B | $4.16B | $1.29B | $734.26M | $19.58 |
 ONC Beone Medicines Ltd Adr | $40.86B | $6.13B | $655.71M | $1.33B | $4.48 |
Ascendis Pharma A S Stock (ASND) Upgrades & Downgrades
Ascendis Pharma A S Stock (ASND) Financials Data
There is no financial data for Ascendis Pharma A S (ASND). Check out other stocks for more information.
Ascendis Pharma A S Stock (ASND) Insider Trading
- Bodenhoff MadsSep 08 '26SVP & PAO
- Transaction
- Option Exercise
- Cost
- $110.00
- #Shares
- 3,000
- Value ($)
- 330,000
- #Shares Total
- 3,000
- Bodenhoff MadsSep 08 '26SVP & PAO
- Transaction
- Sale
- Cost
- $270.19
- #Shares
- 3,000
- Value ($)
- 810,570
- #Shares Total
- 0
- Bodenhoff MadsSep 08 '26Officer
- Transaction
- Proposed Sale
- Cost
- $270.19
- #Shares
- 3,000
- Value ($)
- 810,563
- #Shares Total
- 0
- HOLTUG LARSSep 02 '26Director
- Transaction
- Sale
- Cost
- $264.13
- #Shares
- 236
- Value ($)
- 62,335
- #Shares Total
- 4,000
- HOLTUG LARSSep 02 '26Director
- Transaction
- Proposed Sale
- Cost
- $264.13
- #Shares
- 236
- Value ($)
- 62,335
- #Shares Total
- 0
- BIENAIME JEAN JACQUESAug 14 '26Director
- Transaction
- Buy
- Cost
- $246.33
- #Shares
- 2,000
- Value ($)
- 492,654
- #Shares Total
- 2,900
- SMITH SCOTT THOMASJun 02 '26EVP & Chief Financial Officer
- Transaction
- Buy
- Cost
- $219.00
- #Shares
- 100
- Value ($)
- 21,900
- #Shares Total
- 4,367
- BIENAIME JEAN JACQUESMay 29 '26Director
- Transaction
- Buy
- Cost
- $223.12
- #Shares
- 500
- Value ($)
- 111,562
- #Shares Total
- 900
- SMITH SCOTT THOMASMay 29 '26EVP & Chief Financial Officer
- Transaction
- Buy
- Cost
- $223.32
- #Shares
- 250
- Value ($)
- 55,830
- #Shares Total
- 4,267
- BIENAIME JEAN JACQUESMay 26 '26Director
- Transaction
- Buy
- Cost
- $237.80
- #Shares
- 400
- Value ($)
- 95,120
- #Shares Total
- 400
